Antirejection treatment in kidney transplantation--is there a proved rationale for the general use of monoclonal antibodies?
Reis
H J
HJ
Department of Surgery, University of Tübingen, FRG.
Hopt
U T
UT
Greger
B
B
Schareck
W D
WD
Bockhorn
H
H
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000150:complications; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation; D009894:Opportunistic Infections / Q000150:complications; D013997:Time Factors
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum